7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

DB08550

small molecule experimental

Deskripsi

Potent reversible inhibitor of phenylethanolamine N-methyltransferase.

Struktur Molekul 2D

Berat 202.08
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1162 Data
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Magnesium sulfate The therapeutic efficacy of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Orphenadrine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Pramipexole 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Pramipexole.
Ropinirole 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Ropinirole.
Rotigotine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Sodium oxybate 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Thalidomide 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Apraclonidine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the alpha-adrenergic activities of Apraclonidine.
Atomoxetine The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Atomoxetine.
Betahistine The metabolism of Betahistine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Bezafibrate 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hepatotoxic activities of Bezafibrate.
Buprenorphine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bupropion.
Buspirone The risk or severity of hypertension can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Buspirone.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Cyclobenzaprine Cyclobenzaprine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Cyproheptadine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Cyproheptadine.
Dextromethorphan The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dextromethorphan.
Diethylpropion The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Diethylpropion.
Domperidone The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Domperidone.
Hydrocodone 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Hydromorphone.
Isometheptene 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the sympathomimetic activities of Isometheptene.
Levonordefrin 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Levonordefrin.
Lithium citrate The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lithium citrate.
Lithium carbonate The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lithium hydroxide.
Maprotiline The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Maprotiline.
Mianserin The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Mianserin.
Esmirtazapine The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Esmirtazapine.
Setiptiline The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Setiptiline.
Aptazapine The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Aptazapine.
Mequitazine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Mequitazine.
Methadone The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Methadone.
Methyldopa 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may decrease the hypotensive activities of Methyldopa.
Methylphenidate 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methylphenidate.
Dexmethylphenidate 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Dexmethylphenidate.
Oxycodone 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.
Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Pizotifen 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Pizotifen.
Reserpine The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reserpine.
Tapentadol The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tapentadol.
Tetrabenazine The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tetrabenazine.
Tramadol The risk or severity of serotonin syndrome and seizure can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tramadol.
Trazodone 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Trazodone.
Altretamine Altretamine may increase the orthostatic hypotensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Clemastine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Clemastine.
Doxapram 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Doxapram.
Linezolid The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Linezolid.
Norepinephrine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Norepinephrine.
Mirtazapine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Mirtazapine.
Meperidine The risk or severity of serotonin syndrome and opioid toxicity can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Meperidine.
Tryptophan The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Ethanol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Methylene blue 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Methylene blue.
Atropine The risk or severity of hypertension can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Atropine.
Brimonidine The metabolism of Brimonidine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Morphine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the analgesic activities of Morphine.
Pholcodine Pholcodine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Tetryzoline The risk or severity of hypertension can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tetryzoline.
Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Valsartan 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Valsartan.
Ramipril 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ramipril.
Esmolol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Esmolol.
Betaxolol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Betaxolol.
Remikiren 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Remikiren.
Torasemide 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Torasemide.
Bethanidine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bethanidine.
Guanadrel 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanadrel.
Metoprolol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metoprolol.
Isradipine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Isradipine.
Olmesartan 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Olmesartan.
Chlorthalidone 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Chlorthalidone.
Nitroprusside 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitroprusside.
Atenolol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Atenolol.
Diltiazem 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Diltiazem.
Minoxidil 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Minoxidil.
Timolol 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Timolol.
Treprostinil 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Treprostinil.
Amlodipine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Amlodipine.
Nimodipine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nimodipine.
Nisoldipine 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nisoldipine.
Bendroflumethiazide 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bendroflumethiazide.
Prazosin 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Prazosin.
Fosinopril 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fosinopril.
Trandolapril 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trandolapril.

Target Protein

Alpha-2B adrenergic receptor ADRA2B
Alpha-2C adrenergic receptor ADRA2C
Alpha-2A adrenergic receptor ADRA2A
Phenylethanolamine N-methyltransferase PNMT

Referensi & Sumber

Synthesis reference: Kenneth G. Holden, Carl D. Perchonock, "Method for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline." U.S. Patent US4200754, issued February, 1976.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul